Literature DB >> 29051064

Harnessing the cross-talk between tumor cells and tumor-associated macrophages with a nano-drug for modulation of glioblastoma immune microenvironment.

Tong-Fei Li1, Ke Li2, Chao Wang1, Xin Liu1, Yu Wen1, Yong-Hong Xu3, Quan Zhang1, Qiu-Ya Zhao1, Ming Shao1, Yan-Ze Li1, Min Han4, Naoki Komatsu5, Li Zhao6, Xiao Chen7.   

Abstract

Glioblastoma (GBM) is the most frequent and malignant brain tumor with a high mortality rate. The presence of a large population of macrophages (Mφ) in the tumor microenvironment is a prominent feature of GBM and these so-called tumor-associated Mφ (TAM) closely interact with the GBM cells to promote the survival, progression and therapy resistance of the GBM. Various therapeutic strategies have been devised either targeting the GBM cells or the TAM but few have addressed the cross-talks between the two cell populations. The present study was carried out to explore the possibility of exploiting the cross-talks between the GBM cells (GC) and TAM for modulation of the GBM microenvironment through using Nano-DOX, a drug composite based on nanodiamonds bearing doxorubicin. In the in vitro work on human cell models, Nano-DOX-loaded TAM were first shown to be viable and able to infiltrate three-dimensional GC spheroids and release cargo drug therein. GC were then demonstrated to encourage Nano-DOX-loaded TAM to unload Nano-DOX back into GC which consequently emitted damage-associated molecular patterns (DAMPs) that are powerful immunostimulatory agents as well as indicators of cell damage. Nano-DOX was next proven to be a more potent inducer of GC DAMPs emission than doxorubicin. As a result, Nano-DOX-damaged GC exhibited an enhanced ability to attract both TAM and Nano-DOX-loaded TAM. Most remarkably, Nano-DOX-damaged GC reprogrammed the TAM from a pro-GBM phenotype to an anti-GBM phenotype that suppressed GC growth. Finally, the in vivo relevance of the in vitro findings was tested in animal study. Mice bearing orthotopic human GBM xenografts were intravenously injected with Nano-DOX-loaded mouse TAM which were found releasing drug in the GBM xenografts 24h after injection. GC damage was evidenced by the induction of DAMPs emission within the xenografts and a shift of TAM phenotype was detected as well. Taken together, our results demonstrate a novel way with therapeutic potential to harness the cross-talk between GBM cells and TAM for modulation of the tumor immune microenvironment.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer cell; Cancer-associated macrophage; Cross-talk; Glioblastoma; Nano-drug

Mesh:

Substances:

Year:  2017        PMID: 29051064     DOI: 10.1016/j.jconrel.2017.10.024

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  23 in total

Review 1.  Leveraging the interplay of nanotechnology and neuroscience: Designing new avenues for treating central nervous system disorders.

Authors:  Elizabeth S Smith; Joshua E Porterfield; Rangaramanujam M Kannan
Journal:  Adv Drug Deliv Rev       Date:  2019-03-04       Impact factor: 15.470

Review 2.  Kinetics of Nanomedicine in Tumor Spheroid as an In Vitro Model System for Efficient Tumor-Targeted Drug Delivery With Insights From Mathematical Models.

Authors:  Sayoni Maitra Roy; Vrinda Garg; Sourav Barman; Chitrita Ghosh; Amit Ranjan Maity; Surya K Ghosh
Journal:  Front Bioeng Biotechnol       Date:  2021-12-01

Review 3.  Recent development of contrast agents for magnetic resonance and multimodal imaging of glioblastoma.

Authors:  Danping Zhuang; Huifen Zhang; Genwen Hu; Bing Guo
Journal:  J Nanobiotechnology       Date:  2022-06-16       Impact factor: 9.429

4.  Ultrasmall Nanoparticle Delivery of Doxorubicin Improves Therapeutic Index for High-Grade Glioma.

Authors:  Virginia Aragon-Sanabria; Anusha Aditya; Li Zhang; Ulrich Wiesner; Michelle S Bradbury; Feng Chen; Barney Yoo; Tianye Cao; Brian Madajewski; Rachel Lee; Melik Z Turker; Kai Ma; Sebastien Monette; Peiming Chen; Jing Wu; Shutian Ruan; Michael Overholtzer; Pat Zanzonico; Charles M Rudin; Cameron Brennan
Journal:  Clin Cancer Res       Date:  2022-07-01       Impact factor: 13.801

Review 5.  Chemically Engineered Immune Cell-Derived Microrobots and Biomimetic Nanoparticles: Emerging Biodiagnostic and Therapeutic Tools.

Authors:  Leila Pourtalebi Jahromi; Mohammad-Ali Shahbazi; Aziz Maleki; Amir Azadi; Hélder A Santos
Journal:  Adv Sci (Weinh)       Date:  2021-03-01       Impact factor: 16.806

Review 6.  Targeting Glioblastoma Tumor Microenvironment.

Authors:  Megan Butler; Sahdeo Prasad; Sanjay K Srivastava
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

Review 7.  In Vitro Glioblastoma Models: A Journey into the Third Dimension.

Authors:  Mayra Paolillo; Sergio Comincini; Sergio Schinelli
Journal:  Cancers (Basel)       Date:  2021-05-18       Impact factor: 6.639

Review 8.  Macrophages/Microglia in the Glioblastoma Tumor Microenvironment.

Authors:  Jun Ma; Clark C Chen; Ming Li
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

Review 9.  Nanoparticles as immunomodulators and translational agents in brain tumors.

Authors:  Adam J Grippin; Kyle A Dyson; Sadeem Qdaisat; James McGuiness; Brandon Wummer; Duane A Mitchell; Hector R Mendez-Gomez; Elias J Sayour
Journal:  J Neurooncol       Date:  2020-08-05       Impact factor: 4.130

10.  Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer.

Authors:  Shen-Jun Yuan; Yong-Hong Xu; Chao Wang; Hui-Chao An; Hua-Zhen Xu; Ke Li; Naoki Komatsu; Li Zhao; Xiao Chen
Journal:  J Nanobiotechnology       Date:  2019-10-17       Impact factor: 10.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.